Clinical Trial Detail

NCT ID NCT03308942
Title Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Tesaro, Inc.
Indications

lung non-small cell carcinoma

Therapies

Niraparib

Age Groups: adult senior

Additional content available in CKB BOOST